Biomarkers in Cancer Research - High Unmet Need in Cervical Cancer and Lung Cancer to Drive Growth01 Nov 2010 • by Natalie Aster
“Biomarkers in Cancer Research - High Unmet Need in Cervical Cancer and Lung Cancer to Drive Growth” by GBI Research provides key data, information and analysis of the major trends and issues affecting the biomarkers in cancer research. The report gives a comprehensive insight into the history of biomarkers, their uses, efficiency as well as their limitations. The report also covers a detailed analysis of the cancer biomarkers market characterization in terms of its market size, segmentation by key cancer types and the major market drivers and barriers.
The report on Biomarkers in Cancer Research highlights the detailed analysis of the major partnership deals that have taken place in the cancer biomarkers market since 2006 along with segmentation by number of deals per year, indication, deal type, geography and companies. In addition, the report also talks about the major M&A deals in the cancer biomarkers market since 2005 along with segmentation by value, geography and companies.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts.
Published: Sep, 2010
Price: US$ 3,500.00
The Global Cancer Biomarkers Market will grow from $3.6 billion in 2007 to $6.3 billion in 2016.
The global cancer biomarkers market for 2007 was estimated to be $3.6 billion and is expected to grow at a CAGR (Compounded Annual Growth Rate) of 6.3% to reach $6.3 billion by 2016.
This growth is primarily attributed to the rise in the number of biomarker tests in the cancer types such as cervical cancer, NSCLC (non-small cell lung cancer), breast cancer, gastric cancer, head cancer, colon cancer and many others that will be launched in the next few years. These will contribute significantly to market revenues. In addition, the support from regulatory bodies such as the FDA (Food and Drug Administration) and various government initiatives will also drive up the investment in biomarkers, which will result in the discovery of improved tumor markers.
Growth of Personalized Medicine and Strong Regulatory Support Will Drive the Future Growth for Biomarkers in Cancer Research
In the future, the growth of personalized medicines and the strong support from regulatory agencies such as the FDA will be the two major factors that will drive the demand for biomarkers, particularly in cancer research. Personalized medicines are gaining popularity due to their ability to provide customized treatment to patients based on their genetic as well as medical profile. Since biomarkers help in predicting patient response to a compound, personalized medicine are increasingly using biomarkers to identify the patient population set that is more likely to respond to a particular drug therapy. Personalized medicines are also increasingly being used in targeted cancer therapies. Thus, going forward, as personalized medicines gain more importance and popularity, the demand for biomarkers is also expected to increase.
In addition, strong support from regulatory agencies such as the FDA is also expected to increase the demand for biomarkers. The FDA has been strong in advocating the use of biomarkers in drug discovery research. It has also formed associations that work towards the classification and discovery of exploratory biomarkers, for qualifying and validating them for use in the clinical process. Biomarkers have also found place in the list of critical path opportunities of FDA, a list released in 2006 enlisting the areas where maximum improvement was needed in terms of new products development. In addition, it is expected that the FDA will provide faster, flexible, simpler and more practical regulatory norms and validation procedures for biomarkers. Thus, the favorable regulatory environment for biomarkers is expected to increase the demand for biomarkers in the future.
Breast Cancer, Prostate Cancer and Colorectal Cancer dominate the Strong Biomarkers Pipeline
The cancer biomarkers pipeline is strong with a total of 274 tests under various stages of development in the numerous cancer areas, dominated largely by breast cancer, prostate cancer and colorectal cancer. These three cancers occupy almost 60% of the entire pipeline. The other two major cancer types in the biomarkers pipeline are ovarian cancer and lung cancer with shares of 14% each.
Some of the leading breast cancer tests in the late stage pipeline include the GP88 Tissue Biopsy Test from A&G Pharmaceuticals and Mammostrat Basal and Mammostrat erbB2 Assay from Clarient, Inc. In respect of prostrate cancer, the leading biomarkers in the late stage research include p2PSA (prostate specific antigen) prostate test from Beckman Coulter, Inc. and NADiA® ProsVue™ from IRIS International Inc. Epigenomics AG’s DNA-methylation biomarker mSEPT9 and Signature Diagnostics AG’s blood based screening test Detector C are the two major biomarkers in the approval stage for colorectal cancer.
The four other smaller cancer types (cervical, pancreatic, stomach and head & neck) account for the remaining 13% of the total pipeline.
To order the report or ask for sample pages contact firstname.lastname@example.org